Financings in Brief: Interpore
This article was originally published in The Gray Sheet
Executive SummaryInterpore: Adopts shareholder rights plan, under which shareholders of record on Sept. 22 will receive one preferred share purchase right for each share of common held; each right enables the purchase of one one-hundredth of a share of Series F junior participating preferred stock for $33. The rights "will be exercisable if a person or group acquires 20% or more of the company's common stock or announces a tender offer for 20% or more" of the stock...
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.